Pharmacoeconomics

Article	Citations
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)	443
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	139
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers	68
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study	65
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study	52
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment	50
The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia	48
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	48
EQ-5D-Y Value Set for Slovenia	47
Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	41
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review	38
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice	37
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review	35
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension	34
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel	32
Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden	29
Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review	28
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine	27
Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis	26
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review	26
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	24
Overlap of Depressive Symptoms with Health-Related Quality-of-Life Measures	23
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States	23
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review	23
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups	23

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective	23
The Application and Implications of Novel Deterministic Sensitivity Analysis Methods	21
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA	21
EQ-5D-Y Value Set for Germany	20
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review	20
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates	20
A Comparison of PROPr and EQ-5D-5L Value Sets	20
Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden	20
Estimating an EQ-5D-Y-3L Value Set for China	19
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment	19
Economic Implications of Endometriosis: A Review	19
Developing the EQ-5D-5L Value Set for Uganda Using the ‘Lite’ Protocol	18
The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe	18
Value Set for the EQ-5D-Y-3L in Hungary	18
Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer	17
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US	17
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma	17
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review	17
A Value Set for the EQ-5D-Y-3L in the Netherlands	16
Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic	16
Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US	15
Economic Impact of Insufficient and Disturbed Sleep in the Workplace	15
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	15
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine	15
Modifying NICE’s Approach to Equity Weighting	15
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer	15
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review	15
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	15
The Challenges of Measuring Informal Care Time: A Review of the Literature	15
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia	15
Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects	14
Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review	14
The EQ-5D-5L Valuation Study in Egypt	14
Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study	14
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder	13
Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments	13
Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest	13
Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations	13
Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness	13
The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies	12
Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management	12
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework	12
Valuing the Quality-of-Life Aged Care Consumers (QOL-ACC) Instrument for Quality Assessment and Economic Evaluation	12
Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening	12
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	12
Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review	12
Living Health Technology Assessment: Issues, Challenges and Opportunities	11
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	11
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review	11
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision	11

Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature	11
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)	11
Do Costs in the Education Sector Matter? A Systematic Literature Review of the Economic Impact of Psychosocial Problems on the Education Sector	10
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability	10
A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets	10
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA	10
Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic	9
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	9
The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature	9
Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers	9
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study	9
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review	9
Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals	9
The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)	9
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA	9
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	9
Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods	9
Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience	8
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	8
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England	8
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden	8
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	8
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review	8
Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial	8
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	8
Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers	8
Assessments of the Value of New Interventions Should Include Health Equity Impact	8
RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt	8
How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents	8
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population	8
In a Child’s Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives	8
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland	8
Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values	8
A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom	8
Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service	8
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial	8
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review	8
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	8
Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance	7
Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis	7
Exploring the Issues of Valuing Child and Adolescent Health States Using a Mixed Sample of Adolescents and Adults	7
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada	7
Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis	7
Four Aspects Affecting Health Economic Decision Models and Their Validation	7
Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review	7
EQ-5D-Y Population Norms for Japanese Children and Adolescents	7
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review	7
Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?	7
Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare	7
An EQ-5D-Y-3L Value Set for Belgium	7
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review	6
The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions	6
Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment	6
Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop	6
Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries	6
Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study	6
Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency	6
Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L	6
Calibrating Natural History of Cancer Models in the Presence of Data Incompatibility: Problems and Solutions	6
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia	6
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force	6
Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis	6
An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year	6
A Framework for the Fair Pricing of Medicines	6
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries	6
Valuing SF-6Dv2 in Australia Using an International Protocol	6
Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis	6
Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031	6
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS	6
Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk-Adjusted Performance Measures and Expected-Utility Approaches	6
The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice	6
Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis	6
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies	6
Psychometric Properties of Generic Preference-Weighted Measures for Children and Adolescents: A Systematic Review	6
How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe	6
Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment	6
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the Unit	6
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process	5
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies	5
An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia	5

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a U	5
Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Base	5
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States	5
Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success	5
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects	5
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial	5
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations	5
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease	5
In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era	5
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated	5
Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia	5
Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors	5
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations	5
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	5
Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway	5
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	5
What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK	5
Modelling the Cost-Effectiveness of Diagnostic Tests	5
Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Stud	5
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry	5
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments	5
Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations	4
Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses	4
A Comparison of Methods for Identifying Informal Carers: Self-Declaration Versus a Time Diary	4
Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries	4
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis	4
Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L	4
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	4
Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis	4
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L	4
Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review	4
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis	4
Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network	4
Macrovascular Risk Equations Based on the CANVAS Program	4
Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs	4
Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation	4
HTA Barriers for Conditional Approval Drugs	4
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective	4
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom	4
Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions	4
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer	4
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	4
Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States	4
Conducting Trial-Based Economic Evaluations Using R: A Tutorial	4
Modelling Spillover Effects on Informal Carers: The Carer QALY Trap	4
Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?	4
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses	4
Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment	3
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal	3
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies	3
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort	3
Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review	3
The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer	3
Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions	3
China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population	3
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds	3
Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review	3
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time	3
Lifetime Costs for Treated Follicular Lymphoma Patients in the US	3
Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models	3
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review	3
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?	3
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting	3
Palliative Care Costs in Different Ambulatory-Based Settings: A Systematic Review	3
Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions	3
Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”	3
NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests	3
EQ-5D-5L Value Set for Slovenia	3
The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance	3
Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery	3
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE	3
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrin	3
Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries	3
Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs	3
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy	3
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus	3
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models	3
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome	3
Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia	3